Erdafitinib is an oral fibroblast growth factor receptor (FGFR) kinase inhibitor that has been approved by the FDA for the treatment of adults with advanced bladder cancer harboring susceptible FGFR3 genetic alterations, particularly in patients who have progressed after at least one line of systemic therapy, including PD-1 or PD-L1 inhibitors (Ascione et al., 2023). Here, CD274 is linked to urinary bladder cancer.